{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:43:40Z","timestamp":1787010220954,"version":"build-2736575974"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>All guidelines for the management of heterozygous familial hypercholesterolaemia in children and young people recommend statins to lower LDL-cholesterol (LDL-C) concentrations, to reduce the individual's adult risk of developing cardiovascular disease (CVD). Here, we review recent findings regarding the efficacy and safety of the use of stains in childhood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>As expected from their safety profile in adults, there is no evidence from short-term trials or long-term follow-up that statin use in children is associated with any adverse effects on growth, pubertal development or muscle or liver toxicity. Long-term follow-up indicates benefits with respect to lower CVD rates. Factors that influence adherence are discussed, as is the role of the underlying genetic causes for hypercholesterolaemia and of variation at other genes in determining the LDL-C-lowering effect.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Based on the good safety profile, and the expert opinion guidelines, clinicians should consider prescribing statins for children with hypercholesterolaemia from the age of at least 10 years (and earlier if CVD risk is particularly high in the family). Uptitrating statin dosage and the use of additional lipid-lowering therapies should be considered so that LDL-C concentrations are lowered to recommended targets.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mop.0000000000000943","type":"journal-article","created":{"date-parts":[[2020,8,23]],"date-time":"2020-08-23T18:00:08Z","timestamp":1598205608000},"page":"633-640","source":"Crossref","is-referenced-by-count":8,"title":["Management of familial hypercholesterolaemia in childhood"],"prefix":"10.1097","volume":"32","author":[{"given":"Uma","family":"Ramaswami","sequence":"first","affiliation":[{"name":"Lysosomal Disorders Unit, Royal Free Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve E.","family":"Humphries","sequence":"additional","affiliation":[{"name":"Centre for Cardiovascular Genetics, Institute Cardiovascular Science, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,8,22]]},"reference":[{"key":"R1-20230918","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.atherosclerosis.2019.05.017","article-title":"Risk of cardiovascular disease outcomes in primary care subjects with familial hypercholesterolaemia: a cohort study","volume":"287","author":"Iyen","year":"2019","journal-title":"Atherosclerosis"},{"key":"R2-20230918","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.atherosclerosis.2018.11.014","article-title":"Coronary heart disease mortality in severe vs. non-severe familial hypercholesterolaemia in the Simon Broome Register","volume":"281","author":"Humphries","year":"2019","journal-title":"Atherosclerosis"},{"key":"R3-20230918","doi-asserted-by":"crossref","first-page":"e016461","DOI":"10.1136\/bmjopen-2017-016461","article-title":"Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis","volume":"7","author":"Akioyamen","year":"2017","journal-title":"BMJ Open"},{"key":"R4-20230918","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1093\/eurheartj\/ehv157","article-title":"Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment","volume":"36","author":"Wiegman","year":"2015","journal-title":"Eur Heart J"},{"key":"R5-20230918","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2019.09.005","article-title":"Current management of children and young people with heterozygous familial hypercholesterolaemia \u2013 HEART UK statement of care","volume":"290","author":"Ramaswami","year":"2019","journal-title":"Atherosclerosis"},{"key":"R6-20230918","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.jacl.2018.02.021","article-title":"Sex differences in cholesterol levels from birth to 19 years of age may lead to increased cholesterol burden in females with FH","volume":"12","author":"Holven","year":"2018","journal-title":"J Clin Lipidol"},{"key":"R7-20230918","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.atherosclerosis.2019.11.012","article-title":"Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries","volume":"292","author":"Ramaswami","year":"2020","journal-title":"Atherosclerosis"},{"key":"R8-20230918","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"key":"R9-20230918","first-page":"CD006401","article-title":"Statins for children with familial hypercholesterolemia","volume":"2019","author":"Vuorio","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"R10-20230918","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jacl.2017.11.005","article-title":"The UK Paediatric Familial Hypercholesterolaemia Register: statin-related safety and 1-year growth data","volume":"12","author":"Humphries","year":"2018","journal-title":"J Clin Lipidol"},{"key":"R11-20230918","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jpeds.2019.03.032","article-title":"Intermediate-term efficacy and tolerance of statins in children","volume":"210","author":"Mamann","year":"2019","journal-title":"J Pediatr"},{"key":"R12-20230918","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa1816454","article-title":"20-Year follow-up of statins in children with familial hypercholesterolemia","volume":"381","author":"Luirink","year":"2019","journal-title":"N Engl J Med"},{"key":"R13-20230918","doi-asserted-by":"crossref","first-page":"e030290","DOI":"10.1136\/bmjopen-2019-030290","article-title":"Enablers and barriers to treatment adherence in heterozygous familial hypercholesterolaemia: a qualitative evidence synthesis","volume":"9","author":"Kinnear","year":"2019","journal-title":"BMJ Open"},{"key":"R14-20230918","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s12687-018-0373-5","article-title":"Parents\u2019 views of genetic testing and treatment of familial hypercholesterolemia in children: a qualitative study","volume":"10","author":"Keenan","year":"2019","journal-title":"J Community Genet"},{"key":"R15-20230918","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.atherosclerosis.2019.01.024","article-title":"Lipid-lowering response in subjects with the p.(Leu167del) mutation in the APOE gene","volume":"282","author":"Bea","year":"2019","journal-title":"Atherosclerosis"},{"key":"R16-20230918","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jacc.2018.05.044","article-title":"Clinical genetic testing for familial hypercholesterolemia: JACC scientific expert panel","volume":"72","author":"Sturm","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"R17-20230918","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1089\/gtmb.2019.0012","article-title":"Independent severe cases of heterozygous familial hypercholesterolemia caused by the W483X and novel W483G mutations in the low-density lipoprotein receptor gene that were clinically diagnosed as homozygous cases","volume":"23","author":"Cheng","year":"2019","journal-title":"Genet Test Mol Biomarkers"},{"key":"R18-20230918","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/cge.13697","article-title":"The familial hypercholesterolaemia phenotype: monogenic familial hypercholesterolaemia, polygenic hypercholesterolaemia and other causes","volume":"97","author":"Mariano","year":"2020","journal-title":"Clin Genet"},{"key":"R19-20230918","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.atherosclerosis.2018.06.006","article-title":"Clinical utility of the polygenic LDL-C SNP score in familial hypercholesterolemia","volume":"277","author":"Futema","year":"2018","journal-title":"Atherosclerosis"},{"key":"R20-20230918","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy \u2013 a genome-wide study","volume":"359","author":"Link","year":"2008","journal-title":"N Engl J Med"},{"key":"R21-20230918","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/jcph.1080","article-title":"Impact of SLCO1B1 genotype on pediatric simvastatin acid pharmacokinetics","volume":"58","author":"Wagner","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"R22-20230918","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1002\/cpt.1330","article-title":"Impact of genetic variation on pravastatin systemic exposure in pediatric hypercholesterolemia","volume":"105","author":"Wagner","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"R23-20230918","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/cts.12749","article-title":"Impact of SLCO1B1 genetic variation on rosuvastatin systemic exposure in pediatric hypercholesterolemia","volume":"13","author":"Wagner","year":"2020","journal-title":"Clin Transl Sci"},{"key":"R24-20230918","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.jacl.2018.05.007","article-title":"Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: rationale and design of the HAUSER-RCT study","volume":"12","author":"Gaudet","year":"2018","journal-title":"Clin Lipidol"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000000943","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T22:18:18Z","timestamp":1694989098000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000000943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,22]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000000943","relation":{},"ISSN":["1040-8703","1531-698X"],"issn-type":[{"value":"1040-8703","type":"print"},{"value":"1531-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,22]]}}}